Regeneron Pharmaceuticals
REGN· Manufacturing· Fiscal year ends in December
Leonard S. Schleifer, M.D., Ph.D. is the CEO of Regeneron Pharmaceuticals and was paid $6.8M in FY2024 (Dec), down 17%.
Executives6
See all- 1Daniel P. Van PlewExecutive Vice President and General Manager, Industrial Operations and Product SupplyFY2024
- 2Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific OfficerFY2024
- 3Leonard S. Schleifer, M.D., Ph.D.Board co-Chair, President and Chief Executive OfficerFY2024
- 4George D. Yancopoulos, M.D., Ph.D.Ph.D. Board co-Chair, President and Chief Scientific OfficerFY2024
- 5Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer6FY2024
- 6Joseph J. LaRosaExecutive Vice President, General Counsel and Secretary10Not disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allRegeneron Pharmaceuticals paid its 6 named executives $37.2M in total in FY2024 (Dec). CEO Leonard S. Schleifer, M.D., Ph.D. was paid $6.8M of that.
| Name | |||
|---|---|---|---|
| Daniel P. Van PlewExecutive Vice President and General Manager, Industrial Operations and Product Supply | |||
| Andrew J. Murphy, Ph.D.Executive Vice President, Co-Chief Scientific Officer | |||
| Leonard S. Schleifer, M.D., Ph.D.Board co-Chair, President and Chief Executive Officer | |||
| George D. Yancopoulos, M.D., Ph.D.Ph.D. Board co-Chair, President and Chief Scientific Officer | |||
| Christopher FenimoreExecutive Vice President, Finance and Chief Financial Officer6 | Not disclosed | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers11
See allThe FY2025 (Dec) proxy of Regeneron Pharmaceuticals names 11 peer companies for pay. Among Regeneron Pharmaceuticals and these peers, CEO pay was the lowest of 8 and total shareholder return was 5th highest of 8.
8th highest of 8in Regeneron Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
5th highest of 8in Regeneron Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Activity
No new filings about this company in the feed.
Filings20
See all| Current report | 8-K | Sep 30, 2026 | — |
| Current report | 8-K | Jun 17, 2026 | — |
| Proxy statement | DEF 14A | Apr 24, 2026 | FY2025 |
| Annual report | 10-K | Feb 4, 2026 | FY2025 |
| Current report | 8-K | Jun 18, 2025 | — |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |